

COMPANY ANNOUNCEMENT

KarmelSonix Launches its PulmoTrack® Cough Counter “Add on Technology” in USA

HIGHLIGHTS

- KarmelSonix has brought to market the first commercial cough monitoring technology
- The Cough Counting optional add-on software package is a novel validated extension of the PulmoTrack® / Wholter™ / WIM-GER™ product-line
- The PulmoTrack-3010-CC was launched last week at the Second American Cough Conference in Jersey City, NJ, USA to a very good reception by the Key Opinion Leaders in attendance

22nd June 2009: The Directors of KarmelSonix Ltd (KSX or the Company) are pleased to announce the launch of the PulmoTrack-3010-Cough Counter (PT-CC), an additional component to the PulmoTrack®, Wholter™ and WIM-GER™.

The launch of PT-CC took place at the Second American Cough Conference held in Jersey City, NJ on 12-13th June 2009. Attendees from the US, UK, Europe, Australia and South America, commented on the importance of the availability of this first commercial quantitative cough monitoring device. Specific interest in the technology covers: (a) clinical and basic research on cough (e.g. monitor the extent of cough in TB patients as a measure of response to treatment); (b) clinical use, primarily to assess chronic cough by 24 hour cough monitoring; and (c) pharmaceutical research to assess existing and new cough medications.

The technology is currently under review by the regulatory authorities both in Europe and USA, awaiting CE mark clearance and FDA approval.

The exhibition was shared with Mr. Jerry Mabary, Vice President of Sandhill Scientific Inc who presented the Zephyr, which, together with the Wholter, will constitute the WIM-GER™. At the event, Mr. Mabary expressed his confidence that the hybrid device will gain as much popularity among pulmonologists and asthma and cough specialists as with gastroenterologists and ear, nose and throat (ENT) doctors.

Commenting on the introduction of the PT-CC, KSX, VP – Sales and Marketing, Mr. Larry Murdock said: “It turns out that chronic and sub-acute cough is a huge market with 2% of visits to primary care physicians (GPs) and paediatricians in the US being for cough as the primary presenting symptom. The Cough Counter will have significant application with the Wholter™ with its ability to properly track the coughing experience of people, the effect of treatments applied particularly nocturnally and to obtain accurate data as to when coughing occurs.

“Wheeze Rate – A New Paradigm in Asthma Management”

Coughs count as one of the most frequent reasons for doctor visits. Out of 829 million doctor visits, almost 30 million are people seeking help for coughs, according to the American College of Chest Physicians.

Feedback from experts in the field clearly indicates that cough monitoring, as a stand-alone feature, is a highly needed technology. With the US FDA recent scrutiny of existing OTC cough remedies, the need is further enhanced in order to provide objective evidence that these drugs are actually effective. This latest development is likely to substantially expand the market for KarmelSonix’ products, beyond its original span covering asthma and COPD management.”

For additional information please contact:

Mr. Peter Marks, Chairman	+61 (0)3 9824 8166	Peter@karmelsonix.com
Prof. Noam Gavriely, Director	+972 544 661 337	Noam@karmelsonix.com

KarmelSonix Ltd. focuses on supplying innovative non-invasive acoustic tools for disease management of asthma and related pulmonary disorders. Asthma affects 6-16% of the population in developed countries with a cost exceeding \$US15 billion in the US alone.

Acoustic Asthma Management is a breakthrough in monitoring of the asthmatic patient of all ages, including the very young, very old and others who cannot perform currently available tests. The technology that comes from extensive R&D and clinical validation in the US, Israel and Australia, facilitate continuous monitoring of patients at home, in the ICU and even during sleep. The company is focused on early commercialization of its products with special emphasis on the European and North American markets.

“Wheeze Rate – A New Paradigm in Asthma Management”